SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The… Read more
SMS Pharmaceuticals Limited (SMSPHARMA) - Net Assets
Latest net assets as of September 2025: ₹7.29 Billion INR
Based on the latest financial reports, SMS Pharmaceuticals Limited (SMSPHARMA) has net assets worth ₹7.29 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹12.76 Billion) and total liabilities (₹5.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹7.29 Billion |
| % of Total Assets | 57.14% |
| Annual Growth Rate | 13.82% |
| 5-Year Change | 55.81% |
| 10-Year Change | 117.86% |
| Growth Volatility | 48.92 |
SMS Pharmaceuticals Limited - Net Assets Trend (2005–2025)
This chart illustrates how SMS Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SMS Pharmaceuticals Limited (2005–2025)
The table below shows the annual net assets of SMS Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹6.40 Billion | +19.26% |
| 2024-03-31 | ₹5.36 Billion | +16.46% |
| 2023-03-31 | ₹4.61 Billion | -2.08% |
| 2022-03-31 | ₹4.70 Billion | +14.56% |
| 2021-03-31 | ₹4.11 Billion | +17.89% |
| 2020-03-31 | ₹3.48 Billion | +8.18% |
| 2019-03-31 | ₹3.22 Billion | +13.16% |
| 2018-03-31 | ₹2.84 Billion | -14.99% |
| 2017-03-31 | ₹3.35 Billion | +13.98% |
| 2016-03-31 | ₹2.94 Billion | +15.25% |
| 2015-03-31 | ₹2.55 Billion | +14.86% |
| 2014-03-31 | ₹2.22 Billion | -9.12% |
| 2013-03-31 | ₹2.44 Billion | +10.39% |
| 2012-03-31 | ₹2.21 Billion | +0.52% |
| 2011-03-31 | ₹2.20 Billion | +3.07% |
| 2010-03-31 | ₹2.13 Billion | +0.58% |
| 2009-03-31 | ₹2.12 Billion | +1.90% |
| 2008-03-31 | ₹2.08 Billion | +13.94% |
| 2007-03-31 | ₹1.83 Billion | +228.54% |
| 2006-03-31 | ₹556.25 Million | +15.76% |
| 2005-03-31 | ₹480.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SMS Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 380092900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹3.80 Billion | 59.42% |
| Common Stock | ₹88.65 Million | 1.39% |
| Other Comprehensive Income | ₹1.30 Billion | 20.40% |
| Other Components | ₹1.20 Billion | 18.79% |
| Total Equity | ₹6.40 Billion | 100.00% |
SMS Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of SMS Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DUOL34
SA:DUOL34
|
$105.58 Million |
|
EUROCELL (WI) LS -001
F:6YQ
|
$105.59 Million |
|
Namchow Chemical Industrial Co Ltd
TW:1702
|
$105.60 Million |
|
Enwei Pharmaceutical Co. Ltd. A
SHE:301331
|
$105.66 Million |
|
KOGENERACJA S.A. ZY 5
F:2ZO
|
$105.56 Million |
|
TrueBlue Inc
NYSE:TBI
|
$105.53 Million |
|
SMARTOPTICS GRP AS NK-02
F:3YL
|
$105.49 Million |
|
Meteoric Resources NL
OTCGREY:METOF
|
$105.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SMS Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,363,289,000 to 6,396,443,000, a change of 1,033,154,000 (19.3%).
- Net income of 691,356,000 contributed positively to equity growth.
- Dividend payments of 33,861,000 reduced retained earnings.
- Share repurchases of 380,903,000 reduced equity.
- New share issuances of 380,903,000 increased equity.
- Other comprehensive income decreased equity by 27,000,000.
- Other factors increased equity by 402,659,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹691.36 Million | +10.81% |
| Dividends Paid | ₹33.86 Million | -0.53% |
| Share Repurchases | ₹380.90 Million | -5.95% |
| Share Issuances | ₹380.90 Million | +5.95% |
| Other Comprehensive Income | ₹-27.00 Million | -0.42% |
| Other Changes | ₹402.66 Million | +6.3% |
| Total Change | ₹- | 19.26% |
Book Value vs Market Value Analysis
This analysis compares SMS Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 34.57x to 5.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹11.72 | ₹405.20 | x |
| 2006-03-31 | ₹13.57 | ₹405.20 | x |
| 2007-03-31 | ₹25.71 | ₹405.20 | x |
| 2008-03-31 | ₹20.82 | ₹405.20 | x |
| 2009-03-31 | ₹21.19 | ₹405.20 | x |
| 2010-03-31 | ₹21.31 | ₹405.20 | x |
| 2011-03-31 | ₹21.96 | ₹405.20 | x |
| 2012-03-31 | ₹22.08 | ₹405.20 | x |
| 2013-03-31 | ₹24.37 | ₹405.20 | x |
| 2014-03-31 | ₹25.09 | ₹405.20 | x |
| 2015-03-31 | ₹30.09 | ₹405.20 | x |
| 2016-03-31 | ₹34.68 | ₹405.20 | x |
| 2017-03-31 | ₹39.53 | ₹405.20 | x |
| 2018-03-31 | ₹33.61 | ₹405.20 | x |
| 2019-03-31 | ₹38.03 | ₹405.20 | x |
| 2020-03-31 | ₹41.14 | ₹405.20 | x |
| 2021-03-31 | ₹48.50 | ₹405.20 | x |
| 2022-03-31 | ₹55.56 | ₹405.20 | x |
| 2023-03-31 | ₹54.40 | ₹405.20 | x |
| 2024-03-31 | ₹63.36 | ₹405.20 | x |
| 2025-03-31 | ₹75.39 | ₹405.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SMS Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.81%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.83%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.80x
- Recent ROE (10.81%) is above the historical average (9.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 17.58% | 7.12% | 0.77x | 3.20x | ₹36.41 Million |
| 2006 | 15.29% | 6.59% | 0.78x | 2.98x | ₹29.45 Million |
| 2007 | 11.47% | 12.11% | 0.58x | 1.63x | ₹26.93 Million |
| 2008 | 13.04% | 12.91% | 0.60x | 1.68x | ₹63.39 Million |
| 2009 | 2.97% | 2.57% | 0.61x | 1.88x | ₹-149.19 Million |
| 2010 | 1.12% | 1.09% | 0.50x | 2.04x | ₹-189.45 Million |
| 2011 | 3.82% | 3.74% | 0.47x | 2.15x | ₹-136.02 Million |
| 2012 | 0.51% | 0.53% | 0.44x | 2.22x | ₹-209.71 Million |
| 2013 | 10.38% | 10.45% | 0.51x | 1.93x | ₹9.18 Million |
| 2014 | 9.19% | 3.93% | 1.02x | 2.30x | ₹-17.96 Million |
| 2015 | 13.83% | 6.08% | 1.07x | 2.12x | ₹97.69 Million |
| 2016 | 13.93% | 6.78% | 0.92x | 2.23x | ₹115.32 Million |
| 2017 | 12.26% | 6.28% | 0.94x | 2.07x | ₹75.76 Million |
| 2018 | 11.16% | 6.89% | 0.92x | 1.77x | ₹33.01 Million |
| 2019 | 12.44% | 8.67% | 0.83x | 1.74x | ₹78.57 Million |
| 2020 | 9.07% | 7.75% | 0.67x | 1.75x | ₹-32.50 Million |
| 2021 | 15.23% | 11.15% | 0.69x | 1.98x | ₹214.74 Million |
| 2022 | 13.23% | 12.08% | 0.60x | 1.83x | ₹151.91 Million |
| 2023 | -1.53% | -1.35% | 0.59x | 1.91x | ₹-531.12 Million |
| 2024 | 9.29% | 7.03% | 0.69x | 1.93x | ₹-38.07 Million |
| 2025 | 10.81% | 8.83% | 0.68x | 1.80x | ₹51.71 Million |
Industry Comparison
This section compares SMS Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $6,309,118,459
- Average return on equity (ROE) among peers: 25.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SMS Pharmaceuticals Limited (SMSPHARMA) | ₹7.29 Billion | 17.58% | 0.75x | $105.56 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.19 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $34.19 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $428.52 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $39.88 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $818.67 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $376.73 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $324.08 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $157.65 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $31.85 Million |